医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

PerkinElmer Launches Automated Workstation for Improved Process Development of Protein Therapeutics

2013年01月22日 AM06:25
このエントリーをはてなブックマークに追加

Smart Multimedia Gallery

 

The JANUS(R) BioTx Pro(TM) automated workstation for improved process development of protein therapeutics (Photo: Business Wire)The JANUS(R) BioTx Pro(TM) automated workstation for improved process development of protein therapeutics (Photo: Business Wire)

View and Share Photo

Close Window


PALM SPRINGS, Fla.

PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment announced the launch of the JANUS® BioTx ProTM automated workstation for improved process development of protein therapeutics at the 12th Annual Protein Science Week (PepTalk), January 21–25 in Palm Springs, Florida at booth #312. Designed for high throughput, small scale protein purification, it is the only workstation that accommodates multiple chromatography modes (column, tip and batch) eliminating the need for multiple instruments, resulting in more efficient and cost effective sample processing.

The JANUS(R) BioTx Pro(TM) automated workstation for improved process development of protein therape ...

The JANUS(R) BioTx Pro(TM) automated workstation for improved process development of protein therapeutics (Photo: Business Wire)

“Sample preparation for protein characterization can be a time consuming and tedious process,” said Kevin Hrusovsky, president Life Sciences and Technology, PerkinElmer “Automating this function frees up valuable research time and enables scientists to obtain critical information earlier in the protein development pipeline. This is particularly important to support quality by design experimentation in both upstream and downstream processes to improve product quality and reduce development time.”

The JANUS BioTx Pro enables small scale purification of µg to mg proteins on one system instead of three individual dedicated systems, supporting the use of commercially available plate and column based screening tools like GE PreDictor plates, PhyNexus PhyTip® columns and Atoll columns. Applications for the workstation include resin binding studies and conditions screening.

On January 24, at 9:50am, at the PepTalk Conference, Jeremy Lambert, Portfolio Director, Automation, will present a talk on PerkinElmer’s Automation and microfluidics technologies including how the JANUS Biotx Pro saves researchers time by automating sample preparation for protein characterization.

PerkinElmer has a portfolio of solutions across the biotherapeutics workflow, from target identification, cloning and expression to safety testing and quality control, to help ensure the consistent, reproducible results that biotherapeutics research and patient safety considerations demand. The portfolio includes the LabChip® GXIITM benchtop microfluidic system for high throughput protein analysis and characterization, and AlphaLISA® assays, a no-wash ELISA alternative technology for biomarker identification, safety testing and toxicity studies.

For more information about PerkinElmer’s biotherapeutics solutions, please visit: http://www.perkinelmer.com/biotherapeutics

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The company reported revenue of approximately $1.9 billion in 2011, has about 7,400 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130121005784/en/

CONTACT

Edelman (On behalf of PerkinElmer, Inc.)
Paul Barren, 404-460-9679
paul.barren@edelman.com

同じカテゴリーの記事 

  • EMS Kegel Trainer BODYDOCTOR Opens New Era of Health Care Solutions in Global Femcare Market
  • EMSケーゲルトレーナー BODYDOCTOR、Femcareのグローバル市場でK-HEALTH CAREに注目が集まる
  • InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
  • METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
  • Poxel to Report Its 2023 Annual Results by the End of April 2024